Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.
Saved in:
| Title: | Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy. |
|---|---|
| Authors: | Kuchimanchi M; Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, 91320, USA., Zhu M; Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, 91320, USA., Clements JD; Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, 91320, USA., Doshi S; Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, 91320, USA. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2019 Apr; Vol. 85 (4), pp. 807-817. Date of Electronic Publication: 2019 Feb 18. |
| Publication Type: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2125 |
|---|---|
| DOI: | 10.1111/bcp.13864 |
